EXOSOMICS

Executive Summary

EXOSOMICS (Rivela Diagnostics) is a private Italian diagnostics company focused on multi-cancer early detection from a simple blood test. Founded in 2011 and based in Siena, the company aims to reduce cancer mortality by enabling earlier, personalized treatment. Their platform leverages exosome analysis to detect multiple cancer types at the earliest stage. While the company has not disclosed specific funding or valuation data, its long-standing presence in the diagnostics space suggests ongoing development. With growing global emphasis on liquid biopsy and early cancer detection, EXOSOMICS is well-positioned to contribute to this rapidly expanding market. The company's progress, however, remains opaque due to limited public disclosures, making it a higher-risk opportunity.

Upcoming Catalysts (preview)

• Q2 2026Publication of clinical validation study for multi-cancer detection panel60% success
• Q4 2026Partnership with major pharma or diagnostics distributor for European commercialization40% success
• Q1 2027CE-IVD marking or FDA breakthrough device designation for lead assay30% success